Jason M. Broderick | Authors

April 22, 2021

Scott T. Tagawa, MD, considers data for the novel PSMA-targeted radiopharmaceutical 177Lu-PSMA-617.

April 15, 2021

Patients with germline and/or homozygous tumor DNA damage response alterations among male patients with heavily pretreated metastatic castration-resistant prostate cancer were most likely to respond to treatment with the PARP inhibitor talazoparib.

April 10, 2021

Maintaining a healthy lifestyle mitigated the genetic risk for lethal prostate cancer in men with high genetic risk.

March 28, 2021

During a presentation at the 14th Annual New York GU Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, Scott T. Tagawa, MD, reviewed important findings related to radium-223 and its use in patients with castration-resistant prostate cancer.

February 14, 2021

Findings from the phase 3 CONDOR trial support the use of the PSMA PET imaging agent 18F-DCFPyL as the FDA prepares to make a decision on a new drug application regarding its use.

February 12, 2021

For patients with chemotherapy-naïve metastatic castration-resistant prostate cancer receiving androgen deprivation therapy, abiraterone acetate and prednisone plus the addition of apalutamide reduced the risk of radiographic progression or death by 30%.

December 06, 2020

Data for a key study secondary outcome measure showed that 56.1% of patients who achieved a complete response to Jelmyto maintained that response at 12 months.

December 05, 2020

Researchers identified the prevalence of germline mutations associated with the early-onset renal cell carcinoma, as well as clinicopathologic factors linked to an increased risk of carrying these mutations.

December 05, 2020

A phase 2 study found that the investigational HIF-2α inhibitor MK-6482 has durable efficacy in patients with Von Hippel-Lindau associated clear cell renal cell carcinoma and non-renal lesions.

December 04, 2020

“Providers should consider using BLC for surveillance of high-risk NMIBC patients undergoing BCG as it could change clinical management by identifying patients who are BCG unresponsive and eligible for alternative therapy and clinical trials,” said Meera Chappidi, MD.